{"disease":{"id":"high-risk-localized-soft-tissue-sarcoma","name":"high risk localized soft tissue sarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05839275","title":"The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05774275","title":"The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Fudan University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}